CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 54.21 USD -4.71% Market Closed
Market Cap: 5.2B USD
Section:
 

Relative Value

The Relative Value of one CRSP stock under the Base Case scenario is 39.2 USD. Compared to the current market price of 54.21 USD, CRISPR Therapeutics AG is Overvalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRSP Relative Value
Base Case
39.2 USD
Overvaluation 28%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

132.7
P/S
P/S
Price to Sales
132.7
vs History
26
vs Industry
15
Median 3Y
38.6
Median 5Y
38.6
Industry
8.2
Forward
326.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-9.8
Industry
24.2
Forward
-8.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-13.2
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-15
Median 5Y
-12.3
Industry
25.5
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
26
vs Industry
43
Median 3Y
2.2
Median 5Y
2.4
Industry
3.3
More Details
82.8
EV/S
EV/S
Enterprise Value to Sales
82.8
vs History
28
vs Industry
18
Median 3Y
21.8
Median 5Y
21.8
Industry
8.6
Forward
203.6
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-5.9
Industry
6.1
Forward
-5.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-5.6
Industry
6.6
Forward
-5.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-10
Median 5Y
-8.3
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-7.5
Industry
6.8
More Details
10
EV/IC
EV/IC
Enterprise Value to IC
10
vs History
26
vs Industry
30
Median 3Y
6.8
Median 5Y
7.9
Industry
5.7
More Details

Multiples Across Competitors

CRSP Competitors Multiples
CRISPR Therapeutics AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
5.1B USD 132.7 -10.4 -6.9 -6.6
IL
Can Fite Biopharma Ltd
TASE:CANF
162.6T ILS 59 083 046.2 -4 057 443.4 -3 981 594.1 -3 972 731.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 170 980.7 -162 409.6 -197 217.1 -194 966.6
US
Abbvie Inc
NYSE:ABBV
383.1B USD 6.4 163.1 15.9 22.5
US
Amgen Inc
NASDAQ:AMGN
177.6B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.5B USD 9.5 30.3 22.2 23.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.7 -526.1 -572.9 -557.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
84.6B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
42.6B EUR 13.7 32.3 55.5 57
P/S Multiple
Revenue Growth P/S to Growth
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
Average P/S: 8 477 842.7
132.7
97%
1.4
IL
C
Can Fite Biopharma Ltd
TASE:CANF
59 083 046.2
140%
422 021.8
FR
Pharnext SCA
OTC:PNEXF
34 170 980.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
1
US
E
Epizyme Inc
F:EPE
2 061.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
P/E Multiple
Earnings Growth PEG
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
Average P/E: 43.7
Negative Multiple: -10.4 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 057 443.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 409.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
163.1
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.3
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
Average EV/EBITDA: 21.9
Negative Multiple: -6.9 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 981 594.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
55.5
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
Average EV/EBIT: 24
Negative Multiple: -6.6 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 972 731.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 966.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
57
N/A N/A

See Also

Summary
CRSP intrinsic value, competitors valuation, and company profile.
DCF Valuation
CRSP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CRSP stock valuation using valuation multiples.
Wall Street Estimates
CRSP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CRSP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.